Angiotech Pharmaceuticals Inc.  (ANPI) Trade Now »     Rate ANPI  -  Discuss ANPI  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ANPI: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Extreme FDA Medical Device Trades: 7 Stocks Under $5 ANPI

73%

-26.06% in 153 days <> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 238 entries as of 7/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio... Continue reading »

FDA Extreme Trades: 16 Stocks Under $5 ANPI

73%

-5.14% in 8 days (closed on 07/05/09) <> Below are FDA extreme trades among 16 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <> <font> Extreme FDA and Clinical Trial Calendar Trade... Continue reading »

Bullish on ANPI ... ANPI

N/A

-29.86% in 161 days <table width="100%"> <tbody> <tr> <td width="60%"> <font> Analysts'  Recommendation: </font> </td> <td width="40%"> <font> Hold   </font> </td> </tr> <tr> <td width="60%"> <font>     30 Days Ago: </font> </td> <td width="40%"> <font> Hold   </font> </td> </tr> <tr height="2"> <td height="2" width="100%"> </td> </tr> </tbody> </table> Continue reading »

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS ANPI

73%

-18.72% in 18 days (closed on 06/27/09) <> Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply bu... Continue reading »

Bullish on ANPI ... ANPI

62%

-36.13% in 185 days Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees Continue reading »

From the Blogosphere

Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:4Kids Entertainment (NYSE: KDE) – no consensusAlbany Molecular Research (NASDAQ: AMRI) – consensus loss $0.04American Electric Tech Inc. (NASDAQ: AETI) – no consensusAmerican Water Works Co Inc. (NYSE: AWK) – consensus EPS $0.54Angiotech Pharmaceuticals (NASDAQ: ANPI) – consensus EPS $0.04Applied Energetics, Inc. (NASDAQ: AERG) – no consensusAssisted Living Concept (NYSE: ALC) – consensus EPS $0.31ATA Inc. (NASDAQ: ATAI) – consensus loss $0.02Boots & Coots,... Continue reading »

BioMed News Bytes: Angiotech, BioSante, HGSI

<><>On 10/19/09, Angiotech Pharma (ANPI) received notice from the FDA that Bio-Seal is a Class III medical device that requires Pre-Market Approval (PMA) for marketing clearance by the Agency. As a result, ANPI is reviewing its options with respect to this product candidate, including possibly appealing this FDA decision, and is discussing the possible preparation of a PMA submission with its partner, Biopsy Sciences, LLC. The Bio-Seal Lung Biopsy Tract Plug System is a novel technology designed to prevent air leaks in patients having lung biopsies by plugging the biopsy track with an expanding... Continue reading »

Unusual 11 Mid-Day Movers 6/8: ANPI, MFRI, RSOL, KERX Higher; XTNT, EMIS, AGEN, AIB Lower

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) <font>40% HIGHER;</font> announced that the U.S. FDA has granted 510(k) clearance for the Option(TM) Inferior Vena Cava Filter in the United States, for use in both permanent and retrievable indications. Click here for the full report.MFRI, Inc. (NASDAQ: MFRI) <font>28.3% HIGHER;</font> reports Q1 EPS of $0.88, compared to $0.06 in the same quarter last year. Revenue for the quarter was $68 million, versus $66 million in Q108.XTENT (Nasdaq: XTNT) <font>25.6% LOWER;</font> correcting today following last week's 500%+ surge on news that it receiv... Continue reading »

Morning Movers 6/8: ANPI, MITI, KERX, DYAX, MSPD, MNKD Higher; AIB, LYG, XTNT, IRE Lower

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) <font>50% HIGHER;</font> announced that the U.S. FDA has granted 510(k) clearance for the Option(TM) Inferior Vena Cava Filter in the United States, for use in both permanent and retrievable indications. Click here for the full report.Micromet, Inc. (Nasdaq: MITI) <font>31% HIGHER;</font> last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma at the 14th Congress of the European Hematology Association, held June 4 to 7 in Berlin, Germany. Blinatumomab is a novel thera... Continue reading »

Analysis of Stem Cell Index YTD

73%

The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). Below is a profile for each company, including a summary of their business and researc... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.